Form 4: ImmunityBio Director Acquires Stock Options
SEC Form 4 Filing
Michael D. Blaszyk, a director of ImmunityBio, Inc., acquired stock options for 77,633 shares on June 11, 2024.
Summary
- On June 11, 2024, Michael D. Blaszyk, a director of ImmunityBio, Inc., acquired stock options for 77,633 shares.
- The exercise price of these options is $5.96.
- The options vest on the earlier of June 11, 2025, or the day before the next annual meeting of stockholders, contingent upon continued service as a Service Provider.
- The options expire on June 11, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option grants. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.
Future Outlook
The vesting of the stock options is contingent upon the reporting person's continued service as a Service Provider, indicating an incentive for continued involvement with ImmunityBio.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder confidence as it shows a director increasing their stake in the company.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of transaction: Michael D. Blaszyk acquired stock options. |
| 06/11/2025 | Earliest vesting date for the stock options, contingent upon continued service. |
| 06/11/2034 | Expiration date of the stock options. |
| 06/13/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.